Medical Oncology
Physician insights on cancer treatment protocols, immunotherapy, targeted therapies, and clinical trial updates.
Recent Discussions
How do you counsel patients referred for abnormal light chain ratio when individual light chains are in normal range?
It appears you are referring to a situation where the uninvolved light chain is quite suppressed and the potentially involved light chain is normal, generating an abnormal ratio. There are other situations such as in CKD where both kappa and lambda light chains will be elevated but the ratio will be...
Should we recommend the COVID-19 booster vaccine to patients who had a DVT or any other complications such as hemolytic anemia or thrombocytopenia from prior vaccine doses?
There are a few case reports of VTE following COVID-19 vaccinations (approximately 10 based on my PubMed review today). However, VTE has a high incidence of 0.1% in the general population and much higher after age 45 (Mary Cushman, PMID 17433897), so determining a causal relationship between the vac...
What hematologic conditions are contraindications for a COVID vaccine?
The short answer is that a history of severe allergic reaction is really the only contraindication to COVID-19 vaccination. Perhaps, patients with systemic mastocytosis might be at increased risk of allergic reaction but I'm not aware of data to support that.The longer answer is a question of timing...
When do you check for EPOR gene mutations in your workup for erythrocytosis, and if found, how do you manage it?
Only consider it in instances where there is a life-long (or at least long-term) erythrocytosis and there is no evidence of a secondary erythrocytosis. There is no role for ASA or HU in these instances. I generally do not use phlebotomy either, unless the hematocrit is extreme and the patient is sym...
For young patients with smoldering multiple myeloma who wish to be treated with lenalidomide, how do you go about harvesting their cells for an autologous transplant?
I have serious reservations with treating smoldering myeloma with lenalidomide and in general, discourage it. That is likely a discussion for another day, but my thoughts on this have been summarized here. In general, we are able to secure permission for 'collect and store', and so I would prefer t...
In a patient with progressive thrombocytosis but negative MPN mutations on peripheral blood, what are your diagnostic and treatment recommendations?
I agree with Dr. @Dr. First Last. A bone marrow biopsy is helpful in a case like the one described as morphology can be informative in distinguishing triple negative ET vs pre-MF vs MF and also CML. I agree with NGS panel to see if there are clonal markers identified, testing for BCR-ABL is critical...
How have you been counseling patients with sickle cell regarding a 3rd COVID vaccine?
People who are elderly or immunosuppressed appear likely to benefit from a 3rd dose of mRNA vaccines. Whether or not this applies to a more general population, including people with sickle cell disease is unknown. Sickle cell disease patients are not immunosuppressed in the typical meaning of this t...
How do you approach the initial dosing of carfilzomib for patients with relapsed multiple myeloma?
A great question and one without a uniform answer! I place a lot of focus on patient quality of life, and one of the recurring themes from patients is the number of visits to the medical center. A twice-weekly regimen of carfilzomib (or bortezomib for that matter), over the course of a year, results...
How would you manage a patient with acquired von Willebrand disease who requires DAPT for arterial disease?
Acquired vWF has many causes: lymphoproliferative disorders; MPN; autoimmune disorders; high flow disorders (Heyde syndrome) and drugs. Treating the underlying disorders would be the safest strategy because DAPT is going to cause bleeding per se in some patients and removing a second cause for bleed...
In the absence of symptoms would you still treat high risk myelofibrosis if transplant ineligible?
If a patient with high risk PMF is not a transplant candidate, any therapy is, by definition, palliative and in the absence of symptoms, the potential risks of therapy would theoretically outweigh its benefits (e.g., anemia, leukopenia, or thrombocytopenia). The presence of asymptomatic leukocytosis...